Advertiser disclosure: BestMedsHub may earn a commission when you sign up with a provider linked on this page. Rankings and recommendations are editorial. Compensation never influences which clinic we recommend or how we describe its protocol.
Hone vs Maximus 2026: TRT vs Enclomiphene Compared
Key Takeaways
- Different mechanisms: Hone replaces testosterone exogenously (Schedule III). Maximus stimulates endogenous production via enclomiphene.
- Fertility: Hone suppresses sperm production. Maximus preserves it. This is the single biggest decision point.
- 2026 cost — Hone: $149/mo Premium + ~$28/mo cypionate = $1,900–$2,300/yr all-in.
- 2026 cost — Maximus: $99.99–$199/mo bundled = $1,440–$2,388/yr including the two $72.50 lab draws.
- Trustpilot (May 2026): Hone ~4.0/5; Maximus ~4.5/5.
- Both require: Two morning testosterone draws, ongoing labs, and operate under DEA Schedule III rules (testosterone) or off-label prescribing (enclomiphene).
Hone Health and Maximus Tribe both treat low testosterone but through different mechanisms. Hone prescribes Schedule III testosterone cypionate at roughly $1,900–$2,300/yr all-in and suppresses fertility. Maximus prescribes enclomiphene + pregnenolone at $1,440–$2,388/yr and preserves fertility by stimulating natural production via the HPT axis. Choose Hone if you want classic TRT and are done having biological children. Choose Maximus if fertility matters or you want to avoid exogenous testosterone.
Hone vs Maximus at a glance — 2026 comparison
| Factor | Hone Health | Maximus Tribe |
|---|---|---|
| Founded | 2020 | 2021 |
| Mechanism | Exogenous testosterone replacement | HPT-axis stimulation (enclomiphene) |
| DEA scheduling | Schedule III (testosterone) | Non-controlled (off-label enclomiphene) |
| Monthly cost | $149 (Premium) + ~$28 medication | $99.99 (annual) to $199 (monthly) |
| Year-one all-in | $1,900–$2,300 | $1,440–$2,388 |
| Fertility impact | Suppresses spermatogenesis | Preserves spermatogenesis |
| Retest cadence | Every 90 days (Premium) | ~90 days initial, then 6 months |
| Money-back guarantee | No | 90 days |
| Trustpilot (May 2026) | ~4.0/5 | ~4.5/5 |
| State availability | 50 states | 50 states |
Pricing verified May 2026. Subject to change.
Mechanism of action: replacement vs. stimulation
The marketing for Hone and Maximus can make them feel like substitutes. Pharmacologically they are not. Understanding the mechanism is the difference between a clinically appropriate choice and an expensive mistake.
Hone Health prescribes testosterone cypionate (injectable), testosterone cream, or troches. These are exogenous testosterone — molecules of the hormone delivered from outside the body. When the brain detects adequate circulating testosterone, the hypothalamus and pituitary throttle back luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates Leydig-cell testosterone production; FSH supports Sertoli-cell spermatogenesis. Suppress LH/FSH long enough and the testes shrink and stop making sperm. This is why exogenous TRT is functionally a contraceptive for many men and why HCG (which mimics LH) is often co-prescribed to maintain testicular function.
Maximus Tribe prescribes enclomiphene — the trans-isomer of clomiphene — typically combined with pregnenolone. Enclomiphene is a selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the hypothalamus. The brain “thinks” estrogen is low, releases more LH and FSH, and the testes respond by producing more endogenous testosterone and continuing spermatogenesis. The result is higher total testosterone without exogenous hormone, with fertility preserved or sometimes improved.
Independent enclomiphene literature on PubMed supports the mechanism. Maximus’s published internal data — roughly 2x baseline total testosterone after twelve weeks — should be read cautiously since it is sponsored, but the direction of effect is consistent with peer-reviewed studies. For a deeper mechanism walkthrough see our 2026 Maximus Tribe review.
2026 pricing breakdown — full annual cost
Hone Health 2026 cost
Hone’s Premium tier — the only tier that includes a full TRT prescription — is $149/mo, or $1,788/yr in membership. An initial $45 testing kit and $65 diagnostic assessment cover the first blood draw; subsequent labs from month three onward are membership-bundled. Medication is billed separately: testosterone cypionate runs roughly $28/mo, anastrozole about $22/mo, and an enclomiphene crossover protocol about $42/mo. The realistic year-one all-in lands at $1,900–$2,300 depending on which medications are stacked.
[provider=”hone”]
Maximus Tribe 2026 cost
Maximus bundles medication into the membership. The annual plan starts at $99.99/mo (introductory) and typically settles at $120/mo, for ~$1,440/yr. Month-to-month is $199/mo, or $2,388/yr. Two upfront lab draws at $72.50 each ($145 total) are required before prescription. A 90-day money-back guarantee meaningfully reduces sign-up risk — neither Hone nor most competitors match this.
[provider=”maximus”]
On pure dollars, the annual Maximus plan is the cheapest option of the two. Hone Premium is roughly $400–$900/yr more expensive depending on medication mix. For the full cost analysis across all DTC and concierge options, see our TRT cost 2026 guide.
Lab requirements: what each clinic tests and when
Both clinics use Quest Diagnostics and LabCorp draw stations. Both require recent labs at intake — typically within 30–90 days. Both will reject an applicant who has not completed two morning total-testosterone draws.
Hone Health baseline panel: total testosterone (two AM draws), free testosterone, estradiol (sensitive assay), SHBG, LH, FSH, prolactin, hematocrit and hemoglobin, PSA (men 40+), lipid panel, comprehensive metabolic panel. Premium membership retests every 90 days in year one and every 6 months thereafter.
Maximus Tribe baseline panel: total testosterone (two AM draws), free testosterone, estradiol, LH, FSH, SHBG, PSA where indicated, CBC, lipid panel. Retesting at 90 days post-initiation, then every 6 months.
The clinically important shared element is hematocrit monitoring. Exogenous TRT (Hone) can drive erythrocytosis — hematocrit above 54% — which raises stroke risk and requires therapy to be held. Enclomiphene (Maximus) is far less likely to cause this because the testosterone rise is endogenous and physiologic rather than supraphysiologic. PSA monitoring is mandatory on both for any man 40 or older per AUA 2024; consult a urologist if PSA rises more than 1.4 ng/mL in twelve months.
Fertility impact — the single biggest difference
This section is the reason this comparison exists. Exogenous testosterone suppresses LH and FSH, which suppresses spermatogenesis. A man on testosterone cypionate without HCG bridging will often see sperm counts drop to near zero within three to six months. Recovery after stopping TRT averages 6–24 months and is not guaranteed.
Enclomiphene does the opposite. By blocking estrogen feedback at the hypothalamus it raises LH and FSH, supports Leydig and Sertoli cell function, and preserves or improves sperm parameters. For any man under roughly 40 who has not completed his family — or any man who is undecided — enclomiphene is the clinically conservative starting point. Hone offers an enclomiphene crossover for members who decide partway through that fertility matters more than originally planned; pivoting requires re-testing and a new protocol.
Side effects compared
Hone (exogenous TRT) side effect profile: erythrocytosis (hematocrit >54%), acne, scalp hair shedding in genetically susceptible men, mood lability in the first 4–8 weeks, lipid shifts (HDL down), sleep apnea exacerbation, testicular atrophy without HCG, infertility. Cardiovascular safety at physiologic replacement doses was reassessed in the FDA’s 2023 post-TRAVERSE labeling update — no new major adverse cardiac event signal at replacement doses, but caution is warranted in men with recent stroke or MI within six months.
Maximus (enclomiphene) side effect profile: visual disturbances (rare, dose-dependent — discontinue immediately if they occur), mood changes, headaches, occasional gynecomastia in a small minority, and the inverse of Hone’s risk — enclomiphene can occasionally raise estradiol enough to require monitoring. Erythrocytosis is uncommon. Overall the enclomiphene profile is milder, which is part of why some men start there even when fertility is not a concern.
Who Hone Health is best for
Hone is best for men who have completed their family or who have no fertility plan, who tolerate or prefer injections, who want a 50-state DTC subscription with 90-day retesting, and who value brand maturity and lab depth. The Premium tier’s monitoring cadence is competitive with concierge clinics at roughly half the price. See our original Hone Health brand review for the long-form take and the 2026 Hone Health review for current pricing.
Who Maximus Tribe is best for
Maximus is best for men preserving fertility, men with mild-to-moderate hypogonadism who respond to LH/FSH stimulation, men who want to avoid Schedule III paperwork and injections, and men who want a 90-day money-back guarantee on first-time hormone therapy. See our original Maximus Tribe brand review and the 2026 Maximus review.
Switching between protocols
Switching from Maximus to Hone is straightforward — discontinue enclomiphene, wait 4–6 weeks, retest, and initiate cypionate if testosterone is still low. Switching from Hone to Maximus is harder. Exogenous testosterone has suppressed the HPT axis and the brain needs time to “wake up.” A typical pivot protocol is to taper testosterone, run HCG and clomiphene/enclomiphene for 8–12 weeks (often called a post-cycle restart), retest, and only then assess whether enclomiphene monotherapy is viable. Most men can pivot successfully, but it is not a one-week transition.
DEA Schedule III and the 2026 telehealth extension
Testosterone is DEA Schedule III under the Anabolic Steroid Control Act of 1990. Enclomiphene is not scheduled. On December 19, 2025 DEA and HHS issued the Fourth Temporary Extension of COVID-era telemedicine flexibilities. Effective January 1, 2026 through December 31, 2026 practitioners may initiate and continue Schedule II–V telehealth prescribing without a prior in-person visit, subject to state law. Both Hone (which prescribes a Schedule III) and Maximus (which prescribes off-label enclomiphene) operate within this framework. DEA has signaled intent to finalize a permanent rule before December 31, 2026 — relevant primarily to Hone members on multi-year cypionate.
Trustpilot, refund policies, and customer support
Verified May 2026: Hone Health holds roughly 4.0/5 on Trustpilot across thousands of reviews, with the most common complaints centered on slow medication shipping and occasional clinician handoffs. Maximus Tribe holds roughly 4.5/5 with the most common complaints focused on shipping delays for the dissolvable tablets. Maximus’s 90-day money-back guarantee is the most aggressive in the category and a meaningful tie-breaker for new patients.
Final verdict — how to choose in 2026
If fertility matters, choose Maximus. If you want classic TRT and have completed your family, choose Hone. If you are unsure, start with Maximus — the worst case is that enclomiphene does not raise your testosterone enough and you pivot to Hone after twelve weeks. The reverse pivot is much harder. For broader context on the full clinic landscape see our best online TRT 2026 guide and the testosterone telehealth hub.
Frequently asked questions
What is the difference between Hone Health and Maximus Tribe?
Hone Health prescribes exogenous testosterone (Schedule III) that replaces what the body produces. Maximus Tribe prescribes enclomiphene + pregnenolone that stimulates the body’s own testosterone production via the HPT axis. The mechanisms produce different fertility, side effect, and monitoring profiles even when total testosterone numbers look similar.
Is Maximus Tribe better than Hone Health for fertility?
Yes. Enclomiphene raises LH and FSH and preserves spermatogenesis. Exogenous testosterone suppresses LH and FSH and impairs spermatogenesis. Men who want to preserve fertility should start with Maximus or pair Hone with HCG bridging under physician supervision.
Which is cheaper in 2026 — Hone or Maximus?
Maximus on the annual plan is cheaper at roughly $1,440/yr including the two upfront $72.50 lab draws. Hone Premium with cypionate runs $1,900–$2,300/yr. Maximus monthly-pay ($199/mo, $2,388/yr) is the most expensive of the four price points.
Can I do enclomiphene instead of testosterone injections?
Yes, if your hypothalamus and pituitary still respond. Enclomiphene works best for men with secondary hypogonadism (intact testicular function but low LH/FSH). Men with primary hypogonadism — testicular failure — usually need exogenous testosterone because the testes cannot respond to LH stimulation.
How long does it take to see results on Hone vs Maximus?
Hone members typically feel libido and energy changes in 2–4 weeks on cypionate. Maximus members typically see total testosterone rise within 4–8 weeks on enclomiphene, with symptomatic improvements over 8–12 weeks. Both clinics retest at the 90-day mark.
Does Hone or Maximus require in-person doctor visits?
Neither requires an in-person clinician visit under the DEA Fourth Temporary Extension through December 31, 2026. Both require an in-person Quest or LabCorp blood draw at baseline and at retesting milestones. Clinician consults are virtual.
Is enclomiphene safer than TRT?
Enclomiphene has a milder side effect profile because the testosterone rise is endogenous and physiologic rather than supraphysiologic. Erythrocytosis is uncommon and fertility is preserved. However “safer” depends on diagnosis — primary hypogonadism still typically needs exogenous testosterone, and enclomiphene has its own side effects including rare visual disturbances.
Can I switch from Maximus to Hone if enclomiphene doesn’t work?
Yes. Maximus’s 90-day money-back guarantee makes this the standard pivot path. Discontinue enclomiphene, wait 4–6 weeks, retest, and start testosterone cypionate via Hone Premium if levels remain low. Most men can complete this transition within 90 days of the initial Maximus retest.
Sources
- American Urological Association — Testosterone Deficiency Guideline (2024 amendment)
- Endocrine Society — Testosterone Therapy in Men With Hypogonadism Clinical Practice Guideline (2018)
- FDA — Testosterone Cypionate labeling, post-TRAVERSE update (2023)
- PubMed — Enclomiphene citrate for secondary hypogonadism, multiple peer-reviewed trials
- DEA.gov — Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities (December 19, 2025)
- Hone Health and Maximus Tribe — clinic pricing and protocol pages, verified May 2026
- Trustpilot — Hone Health and Maximus Tribe public review pages (May 2026)
Medical disclaimer: Testosterone replacement therapy is a long-term medical intervention with risks including erythrocytosis, lipid changes, sleep apnea exacerbation, infertility, and prostate effects. TRT requires a clinical diagnosis of hypogonadism, baseline lab work, and ongoing safety monitoring with a licensed physician. This article is informational only. Consult a board-certified clinician — preferably one with endocrinology or men’s-health training — before initiating, modifying, or discontinuing therapy. Do not source testosterone outside the medical system.
Health Disclaimer: BestMedsHub is not a healthcare provider, telehealth service, pharmacy, or medical organization. We do not prescribe medication, diagnose conditions, render medical opinions, or facilitate clinical consultations. All content is for general informational and comparison purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified physician, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any treatment, medication, supplement, or health program. Never disregard professional medical advice or delay seeking it because of anything you have read on this site. If you think you may have a medical emergency, call your local emergency number immediately.
FDA & Prescription Medication Disclaimer: Prescription medications referenced on this page are available only through a licensed healthcare provider after a clinical evaluation, and may not be appropriate or safe for everyone. Any statements regarding dietary supplements, wellness products, or off-label uses have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary and are not guaranteed. Always read the medication guide and consult your prescriber and pharmacist about side effects, contraindications, and drug interactions.